Merthyr's heavy anti-PD-1 cancer immunotherapy Keytruda Phase 3 clinical trial reaches major endpoint

Today, Theof Theof Mercadon (announced that the company's heavy-duty anti-PD-1 cancer immunotherapy Keytruda, as a second-line therapy, reached the primary end of the phase 3 clinicaltrial in patients with advanced metastatic esophageal cancer and gastroesophageal connectivity tumor
sin patients with a CPS score of 10 at the level of tumor PD-L1 expression, Keytruda statistics significantly improved the total survival (OS) of patients compared to chemotherapyKeytruda
Keytruda is a heavy-duty anti-PD-1 therapy developed by Mercado, which activates T lymphocytes to detect and attack tumor cells by blocking the binding of PD-1 to PD-L1 and PD-L2Since its inception, Keytruda has been approved to treat a variety of types of cancer, including melanoma, lung cancer, head and neck cancer, classic Hodgkin's lymphoma and morein a phase 3 clinical trial called KEYNOTE-181, more than 600 patients with esophageal cancer or gastroesophageal connectivity tumors were randomly treated with Keytruda or a physician-selected chemotherapydrug." These patients have received first-line therapy and symptoms continue to worsenThe main endpoint of the trial was OS in all patients and in patients with PD-L1 CPS to 10results showed that Keytruda reached the main endpoint of the trial in patients with PD-L1 CPS s 10In all patients, however, Keytruda failed to meet statistically significant standards, although it improved OS compared to chemotherapy